Description
The average practice has more than 300 patients with Cognitive Dysfunction Syndrome (CDS), yet only 35 patients are being diagnosed. Neutricks is a new, evidence-based, scientifically proven calcium binding protein (CaBP) that aids in the treatment of CDS. The active ingredient, Apoaequorin, has been proven to protect brain cells by 50% during and after ischemia. Neutricks has proved effective in clinical trials and in independent laboratory research studies using senior dogs in which it was shown to significantly improve learning and accuracy as well as to enhance attention. The recommended dose for Neutricks is 1 tablet per 40 lbs. of bodyweight, and it can be doubled if needed.
